Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma – OncLive
|
Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma
OncLive Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma. There are many drugs approved for patients with metastatic urothelial cancer. |
